Epigenetic reprogramming of a distal developmental enhancer cluster drives SOX2 overexpression in breast and lung adenocarcinoma
Nucleic Acids Research · 2023
DOI: 10.1093/nar/gkad734 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2023. Verfasst von Luis E Abatti und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell and Systems Biology, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms, SOXB1 Transcription Factors. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 183 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Canadian Institutes of Health Research, Canada Foundation for Innovation.
Abstract (Originalsprache)
Enhancer reprogramming has been proposed as a key source of transcriptional dysregulation during tumorigenesis, but the molecular mechanisms underlying this process remain unclear. Here, we identify an enhancer cluster required for normal development that is aberrantly activated in breast and lung adenocarcinoma. Deletion of the SRR124–134 cluster disrupts expression of the SOX2 oncogene, dysregulates genome-wide transcription and chromatin accessibility and reduces the ability of cancer cells to form colonies in vitro. Analysis of primary tumors reveals a correlation between chromatin accessibility at this cluster and SOX2 overexpression in breast and lung cancer patients. We demonstrate that FOXA1 is an activator and NFIB is a repressor of SRR124–134 activity and SOX2 transcription in cancer cells, revealing a co-opting of the regulatory mechanisms involved in early development. Notably, we show that the conserved SRR124 and SRR134 regions are essential during mouse development, where homozygous deletion results in the lethal failure of esophageal–tracheal separation. These findings provide insights into how developmental enhancers can be reprogrammed during tumorigenesis and underscore the importance of understanding enhancer dynamics during development and disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cell and Systems Biology, University of Toronto, Toronto, Ontario, Canada.
- Laboratory of Cell Senescence, Cancer and Aging, Health Research Institute of Santiago de Compostela (IDIS), Xerencia de Xestión Integrada de Santiago (XXIS/SERGAS), Santiago de Compostela, Spain.
- Department of Physiology and Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain.
- Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
- Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
- Department of Computer Science, University of Toronto, Toronto, Ontario, Canada.
ORCID-Profile: Luis E Abatti, Michael M Hoffman, Jennifer A Mitchell
Förderung
- CIHR
- Canadian Institutes of Health Research
- Canada Foundation for Innovation
- Ontario Ministry of Research and Innovation
Zitieren
APA
Abatti, L. E., Lado-Fernández, P., Huynh, L., Collado, M., Hoffman, M. M., & Mitchell, J. A. (2023). Epigenetic reprogramming of a distal developmental enhancer cluster drives SOX2 overexpression in breast and lung adenocarcinoma. Nucleic Acids Research. https://doi.org/10.1093/nar/gkad734
Vancouver
Abatti LE, Lado-Fernández P, Huynh L, Collado M, Hoffman MM, Mitchell JA. Epigenetic reprogramming of a distal developmental enhancer cluster drives SOX2 overexpression in breast and lung adenocarcinoma. Nucleic Acids Research. 2023. doi:10.1093/nar/gkad734
BibTeX
@article{Abatti2023,
author = {Abatti, Luis E and Lado-Fernández, Patricia and Huynh, Linh and Collado, Manuel and Hoffman, Michael M and Mitchell, Jennifer A},
title = {Epigenetic reprogramming of a distal developmental enhancer cluster drives SOX2 overexpression in breast and lung adenocarcinoma},
journal = {Nucleic Acids Research},
year = {2023},
doi = {10.1093/nar/gkad734}
}
EUVIMED